A Study Assesssing The Clinical Course And Prognosis Of The Chronic Hepatitis C (CHC, Genotype 1 And 2) Patients With Post Direct-Acting Antiviral Drugs (DAA) Treatment.
Phase of Trial: Phase IV
Latest Information Update: 27 May 2017
Price : $35 *
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 27 May 2017 New trial record
- 09 May 2017 Results presented at the Digestive Disease Week 2017.